Hypoglycemia

Published on 22/03/2015 by admin

Last modified 22/04/2025

Print this page

This article have been viewed 1441 times

18 Hypoglycemia

Hypoglycemia is the most common endocrine emergency, the most frequent complication of insulin-requiring diabetes, and the principal factor limiting optimization of glycemic control in patients with diabetes mellitus and/or critical illness. When unrecognized and not treated appropriately, significant morbidity—including permanent neurologic deficits and death—may ensue.

The American Diabetes Association Workgroup on Hypoglycemia set the alert level for hypoglycemia at plasma glucose concentrations ≤70 mg/dL (3.9 mmol/L) in patients with diabetes mellitus. When the plasma glucose concentration is less than this threshold value, actions should be undertaken to prevent clinical/symptomatic hypoglycemia.¹ Clinical/symptomatic hypoglycemia is characterized by the Whipple triad: (1) symptoms of hypoglycemia, (2) simultaneous low blood glucose concentration, and (3) relief of symptoms with the administration of glucose. These symptoms may be neurogenic/autonomic or neuroglycopenic (Table 18-1). Symptoms of hypoglycemia are similar in type 1 and type 2 diabetes.² Elderly patients report fewer neurogenic/autonomic symptoms.³ They and all other patients with “hypoglycemia unawareness” have a sevenfold increased risk of severe hypoglycemia. Episodes of hypoglycemia in these patients tend to be recurrent and unpredictable.⁴ “Hypoglycemia unawareness” is the loss of autonomic warning symptoms of developing hypoglycemia. Likely pathogenic mechanisms for hypoglycemia unawareness include recurrent exposure to hypoglycemia, leading to increases in brain glucose uptake and possibly reduced β-adrenergic sensitivity.⁵ Fortunately, scrupulous avoidance of hypoglycemia for a period of weeks to months restores hypoglycemia awareness.^6,⁷

TABLE 18-1 Symptoms of Hypoglycemia

Neurogenic	Neuroglycopenic
THE RESULT OF AN AUTONOMIC RESPONSE	THE RESULT OF BRAIN GLUCOSE DEPRIVATION
Blood glucose <55 mg/dL (3.7 mmol/L)	Blood glucose <45 mg/dL (2.5 mmol/L)
Cholinergic: hunger, sweating, paresthesias	Cognitive impairment
Behavioral change
Adrenergic: tremor, palpitations, anxiety	Psychomotor abnormalities
Seizure and coma

In critically ill patients, however, sedation strongly masks symptoms, so one can only rely on frequent and accurate blood glucose measurements to detect hypoglycemia. The most commonly used definition of hypoglycemia during critical illness is a plasma glucose concentration below 40 mg/dL (2.2 mmol/L) in the absence of symptoms.⁸^–¹⁰ Most reflectance blood glucose meters in home and hospital use have poor precision at low levels of blood glucose.¹¹ Capillary blood glucose testing may not be sufficiently reliable to guide management of blood glucose levels in critically ill patients.¹² The use of arterial blood samples for glucose measurements is recommended. However, anemia in critically ill patients can result in falsely elevated blood glucose measurements and mask hypoglycemia when using these blood glucose meters. Also, the recently developed continuous interstitial glucose monitoring system¹³ and the noninvasive GlucoWatch Biographer¹⁴ are less effective at detecting low blood glucose levels and can have a delayed response to low blood glucose concentrations. Therefore, for diabetes patients, the laboratory measurement of a low plasma glucose concentration in the presence of appropriate symptoms remains the most reliable way to diagnose severe hypoglycemia. In the ICU, measurements of arterial blood glucose concentration using modern blood gas analyzers approach the accuracy of conventional laboratory methods.^8,¹²

Specific characteristics of the patient can also determine whether hypoglycemia will be symptomatic or increase the risk of hypoglycemia. For example, a precipitous fall from hyperglycemia to euglycemia in a patient with diabetes can produce hypoglycemic symptoms.¹⁵ In contrast, hypoglycemia with glucose levels as low as 30 mg/dL (1.7 mmol/L) can occur asymptomatically during fasting in normal women and during pregnancy.¹⁶ Some ICU patient populations, such as those with liver or renal failure and septic shock, are at higher risk for hypoglycemia.¹⁷ The characteristics of the hypoglycemia itself (absolute level, duration) and its treatment (avoiding overcorrection) also play a significant role (Table 18-2).

TABLE 18-2 Risk Factors Involved in Hypoglycemia

Hypoglycemia	Patient
Level of hypoglycemia	Liver failure
Duration	Renal failure
(Over)correction of hypoglycemia	Sepsis or shock
Reperfusion damage	Prior history of diabetes mellitus

Incidence of Severe Hypoglycemia

A retrospective study of adults requiring hospitalization indicated that 0.4% of acute medical admissions per year are hypoglycemia related.¹⁸ Severe hypoglycemia (i.e., with symptoms severe enough to require assistance) occurs commonly in patients with type 1 diabetes.¹⁹ In type 2 diabetes, even with intensive therapy, the risk is probably 100-fold less. Over 6 years of observation in the United Kingdom Prospective Diabetes Study, severe hypoglycemia was reported in 2.4% of patients treated with metformin, 3.3% of those treated with a sulfonylurea, and 11.2% of those treated with insulin.²⁰ As insulin usage among patients with type 2 diabetes increases, it is inevitable that severe hypoglycemia will become more common in daily practice.

With the introduction of tight blood glucose control during ICU stay,⁸ the incidence of blood glucose values below 40 mg/dL (2.2 mmol/L) has been reported to range from 5.1% to 18.7% of patients, depending on the targeted level of blood glucose control and the patient population under study.^8,⁹ With the use of accurate glycemia measurement methodologies and algorithms that advise frequent blood glucose measurements (i.e., every 1–4 hours), the incidence and impact of these brief episodes of hypoglycemia should be minimized.¹⁷

Physiologic Barriers Against Hypoglycemia

The central nervous system (CNS) relies primarily on glucose for the generation of cellular energy. Cells in the CNS have endogenous glucose reserves that are sufficient for only minutes if the supply of glucose from the bloodstream is inadequate. In addition, neurons are unable to synthesize glucose. Finally, the brain cannot use fuels other than glucose during acute hypoglycemia.²¹ Hence, when the brain is acutely deprived of glucose, serious neurologic dysfunction occurs. Accordingly, the body has several mechanisms to maintain the plasma glucose concentration within the narrow range of 60 to 140 mg/dL (3.3–7.7 mmol/L) in both the fed and fasting states. When glucose use exceeds glucose production, the brain senses decreasing blood glucose levels and activates counterregulatory pathways.²² The glucose threshold for activation of these mechanisms is approximately 67 mg/dL (3.6 mmol/L), but this setpoint can be altered by recent hyperglycemia or antecedent hypoglycemia. As glucose levels decline, the first counterregulatory mechanism activated is the suppression of endogenous insulin secretion.²³ Next in the hierarchy of responses is the release of two hormones, glucagon and epinephrine, that antagonize the action of insulin. These hormones activate glycogenolysis and gluconeogenesis and stimulate fatty acid oxidation and protein breakdown to provide substrates for gluconeogenesis. With more severe or prolonged hypoglycemia (>3 hours), increases in growth hormone and cortisol release raise blood glucose levels.

The physiologic responses to hypoglycemia and the glucose threshold at which they occur can be modulated. In type 1 diabetes, the glucagon response to hypoglycemia is lost within 3 years after diagnosis, rendering patients dependent on epinephrine-mediated counterregulation and making them more vulnerable to prolonged episodes of severe hypoglycemia. Exposure to antecedent hypoglycemia diminishes the counterregulatory response to a subsequent episode. The brain adapts to antecedent hypoglycemia by increasing glucose uptake so that a more profound hypoglycemic stimulus is required to trigger sympathoadrenal activation and autonomic symptoms.²⁴ The level of glycemic control also affects counterregulatory thresholds. With strict glycemic control, epinephrine release is not triggered until a lower glucose level is reached.^25,²⁶ Conversely, diabetic patients with poor glycemic control can experience hypoglycemic symptoms when the blood glucose concentration decreases to lower values within the normal or even hyperglycemic range.²⁷

Sequelae

Although severe hypoglycemia induces marked cognitive dysfunction, most patients recover rapidly and completely. The effect of repeated severe hypoglycemia on cognitive function in adults is controversial.^28,²⁹ Although focal neurologic symptoms secondary to severe hypoglycemia occur occasionally, severe and permanent cognitive impairment is usually the result of protracted hypoglycemia, often in association with excessive alcohol consumption. The neuronal regions that are particularly vulnerable to hypoglycemia are the cerebral cortex, the substantia nigra, the basal ganglia, and the hippocampus.

The long-term neurologic effects of hypoglycemia during critical illness are poorly delineated.¹⁷ It appears that brief episodes of hypoglycemia do not cause severe acute brain damage. A recent nested case-control study using more sophisticated neurocognitive tests showed that hypoglycemia mildly aggravated critical illness–induced neurocognitive dysfunction, notably the visuospatial domain.³⁰ This association, however, could not be dissociated from an effect of hyperglycemia or of glucose variability, as the patients who experienced hypoglycemia were also those with more severe hyperglycemia and greater glucose variability.

The overall mortality from severe hypoglycemia is unknown. The mortality rate from alcohol-induced hypoglycemia may be as high as 10% in adults.³¹ About 2% to 4% of deaths in patients with type 1 diabetes have been attributed to hypoglycemia. Severe hypoglycemia is the cause of unexpected overnight deaths in young diabetic patients.³² It may be explained by the impairment of hormonal responses to hypoglycemia during sleep, resulting in sudden cardiac arrhythmias.

The association of hypoglycemia and mortality during critical illness is very controversial.³³^–³⁵ Not only is hypoglycemia more frequent in the most severely ill patients (e.g., those with hepatic or renal failure or septic shock), these spontaneous hypoglycemic episodes also more strongly correlate with mortality risk than hypoglycemia induced by intensive insulin therapy. Nevertheless, as a quality-control measure, intensive insulin therapy in the ICU should be implemented with meticulous monitoring of the incidence of hypoglycemic episodes. The importance of careful monitoring of blood glucose concentration is further emphasized by the demonstration of a tight correlation between blood glucose variability and mortality.³⁶

Differential Diagnosis

A clinical classification of hypoglycemic disorders separates patients who appear to be healthy (with or without coexistent disease) from those who appear to be ill (including those with a predisposing illness and those who are hospitalized). For otherwise healthy patients, the most important causes of fasting hypoglycemia are accidental or factitious drug ingestion and insulinoma. The differential diagnosis in ill or hospitalized patients includes predisposing illness, drug interactions, and other iatrogenic factors (Table 18-3).³⁷

TABLE 18-3 Differential Diagnosis of Hypoglycemia

Insulin treatment of diabetes is the most common cause of hypoglycemia in adults. Risk factors for frequent severe hypoglycemia in type 1 diabetes include lower HbA_1C levels, higher daily insulin dose, longer duration of diabetes, absence of residual C peptide, hypoglycemia unawareness, and a prior history of severe hypoglycemia.¹⁹ Insulin-treated type 2 diabetics are also vulnerable to severe hypoglycemia, especially if their disease is well controlled and they have been on insulin for many years.² Whether intensive insulin therapy increases the incidence of severe hypoglycemia with sequelae is disputed.^38,³⁹ Newer insulin analogs such as glargine and lispro, as well as continuous insulin delivery systems, may lessen the risk of fasting or postprandial severe hypoglycemia.^40,⁴¹

Sulfonylureas are a common cause of severe hypoglycemia. The incidence is higher in the elderly, in patients with renal or liver insufficiency, and with the use of long-acting agents like glibenclamide.⁴² Liver dysfunction prolongs the hypoglycemic activity of gliquidone and repaglinide. Renal insufficiency prolongs the activity of glyburide, chlorpropamide, and nateglinide.⁴³ A crude rate of serious hypoglycemia of 1.23 events per 100 person-years has been reported among elderly users of sulfonylureas.⁴⁴ Sulfonylurea-induced hypoglycemia can be prolonged (up to 27 days), and recurrences can occur after initial normalization of glucose levels.⁴⁵ Discovery of inadvertent or factitious sulfonylurea overdose can help avoid an exhaustive search for insulinoma in patients who present with hyperinsulinemic hypoglycemia.⁴⁶

The metabolism of ethanol depletes hepatocellular levels of nicotinamide adenine dinucleotide, which is a cofactor critical for the entry of substrates into gluconeogenesis pathways.⁴⁷ Ethanol also inhibits cortisol and growth hormone responses and delays the epinephrine response to hypoglycemia.⁴⁸ However, ethanol does not inhibit glycogenolysis, so ethanol-induced hypoglycemia does not occur until hepatic glycogen stores have been depleted (after 8–12 hours of fasting).⁴⁹ There is no correlation between blood ethanol levels (although alcohol is usually detected) and the degree of hypoglycemia. The incidence of alcohol-induced hypoglycemia is generally less than 1% in adults, but hypoglycemic coma is commonly related to ethanol ingestion.⁵⁰

In the absence of a drug or toxic cause, adults with severe fasting hypoglycemia should be evaluated for insulinoma, insulin-secreting tumor of the islets of Langerhans,⁵¹ or unusual causes such as excessive production of insulin-like growth factor II or rapid glucose consumption by tumors, diffuse hepatic dysfunction, septic shock, panhypopituitarism, polyglandular endocrine deficiency syndromes, and autoimmune hypoglycemia. The diagnosis of postprandial (reactive) hypoglycemia remains controversial.⁵²

Evaluation

The first step in the evaluation of a patient with suspected hypoglycemia is documentation of low plasma glucose concentration in the presence of neuroglycopenic symptoms (Figure 18-1). Unless there is an obvious medication-related cause for severe hypoglycemia, blood should be drawn for the measurement of glucose, insulin, and C peptide before the administration of glucose and, when indicated, for the workup of thyroid hormone and cortisol deficiency or uremia. In cases of fasting hypoglycemia, intentional, accidental, or surreptitious ingestion of glucose-lowering medications should be investigated to avoid the lengthy workup for insulinoma.⁵¹ Sulfonylurea ingestion causes elevated insulin and C peptide levels, which mimics the findings associated with an insulinoma. Confirmation of the diagnosis of sulfonylurea ingestion can be made using high-pressure liquid chromatography or radioimmunoassay to detect sulfonylureas in blood or urine. The results of these tests are extremely important for further management.

Figure 18-1 Decision tree for suspected hypoglycemia in adults.

Management

In all cases of suspected severe hypoglycemia, a patent airway and hemodynamic stability should be secured while a rapid bedside estimation of blood glucose concentration is performed. In cases of suspected overdose, emesis should not be induced in a hypoglycemic patient. When alcohol abuse is suspected, thiamine (100 mg IV or IM per day until the patient is consuming a complete diet) should be given to avoid acute Wernicke encephalopathy. Administration of glucose is the fundamental remedy. In awake patients with a protected airway, an initial oral dose of 20 g of glucose works. Examples of oral carbohydrates suitable for the correction of hypoglycemia are flavored glucose tablets and juices and sodas high in sugar content. A response should occur within 10 to 15 minutes and typically lasts 1 to 2 hours. Hence, a snack afterward is recommended to avoid recurrent hypoglycemia.

When patients are unwilling or unable to take oral carbohydrates, IV dextrose (glucose) should be given. The recommended initial dose of 50 mL of 50% dextrose provides 25 g dextrose; within 5 minutes, it produces a mean rise in blood glucose to 220 mg/dL (12.5 mmol/L) from nadir values as low as 20 mg/dL (1.1 mmol/L).⁵³ In ICU patients receiving insulin by continuous IV infusion and also receiving a baseline enteral or intravenous glucose load, a 10-g glucose bolus is usually sufficient to correct hypoglycemia, and the smaller glucose load avoids the need to greatly modify the insulin dosing regimen.⁵⁴ For prolonged hypoglycemia (e.g., caused by sulfonylurea overdose), prolonged dextrose infusion plus octreotide may be required.⁵⁵

Parenteral glucagon directly stimulates hepatic glycogenolysis. Glucagon is effective in restoring consciousness if it is given soon after the onset of hypoglycemic coma. Glucagon is particularly effective in pancreatectomized patients but much less useful in type 2 diabetes, because it stimulates insulin secretion as well as glycogenolysis. Patients with depleted glycogen stores, such as those with alcohol-induced hypoglycemia, may not respond to glucagon. Adverse reactions to glucagon administration include nausea and vomiting, delaying carbohydrate ingestion.

In cases of sulfonylurea overdose, octreotide reverses hyperinsulinemia, reduces dextrose requirements, and prevents recurrent hypoglycemia.⁵⁵ The recommended dose of octreotide as an antidote for sulfonylurea overdose is 50 µg subcutaneously, repeated every 8 hours if necessary. Activated charcoal binds sulfonylureas and can be administered in cases of suspected overdose.

Cerebral edema can complicate severe hypoglycemia and should be suspected when unconsciousness lasts more than 30 minutes following normalization of blood glucose concentration. Treatment with IV mannitol (40 mL of a 20% solution) and glucocorticoids (10 mg of dexamethasone) in addition to IV dextrose is advised.

Annotated References

Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169-3176.

This paper gives a comprehensive overview of the incidence of hypoglycemia and the counterregulatory responses to it.

Diabetes Control and Complications Trial research group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46(2):271-286.

This paper reports on the incidence of hypoglycemia in a multicenter, randomized, controlled clinical trial (N = 1441) of intensive versus conventional diabetes therapy, with an average follow-up of 6.5 years.

Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842-1852.

This paper reports on the long-term neurocognitive function of 1144 patients with type 1 diabetes as an 18-year follow-up of the DCCT study. Severe hypoglycemia appeared not to be worse than poor glycemic control for neurocognitive function.

Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 1999;28(3):555-577.

Therapeutically administered antidiabetic drugs—notably, insulin and sulfonylureas—are the most common causes of hypoglycemia in clinical practice. Nevertheless, an impressive list of other drugs can produce hypoglycemia, as discussed in this review paper.

Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet. 1993;341(8856):1306-1309.

This paper reports the results of a meta-analysis of 16 randomized trials of intensive therapy to estimate its impact on the progression of diabetic retinopathy and nephropathy and the risk of severe hypoglycemia.